ANNUAL REPORT

2016

The Washington University Office of Technology Management (OTM) assists University faculty in the transfer of technology from the lab to the global marketplace. Located in the Cortex district of St. Louis, OTM manages a wide variety of intellectual properties arising from research programs throughout Washington University. OTM acts as a resource for faculty in the areas of patent prosecution, material transfer agreements, marketing, and licensing.

5

8

4

6

910

11

STARTUPSDescriptions of the new companies based

on University IP and founded in FY16

UPDATESSee what’s been happening with a few

existing Washington University startups

QUICK START LICENSELearn more about this new option for

Washington University inventors

TECHNOLOGIES

OUTREACHRead up on the award winners from FY16

and OTM-sponsored events

STATISTICSDetails regarding OTM’s FY16 statistics

and agreement information

STAFFGet to know every member of the OTM

team

Check out some of the exciting new technologies that are being developed

2

Table of Contents

Since its inception in the mid-1980’s, the Office of Technology Management (OTM) at Washington University in St. Louis (WU) has formed numerous commercial partnerships for developing WU technologies. Through these partnerships, WU technologies have gone on to make significant impacts in society. A few examples include the breakthrough diagnostic test for heart attack originating in the lab of Dr. Jack Ladenson, or the lab of Dr. Irving Boime pioneering technology to improve the experience of patients engaged in in vitro fertilization. We’ve also witnessed the success of University-backed startups such as Exegy, which developed the Ticker Plant, a purpose-built appliance that normalizes and distributes real-time market data to latency-sensitive trading applications. As we continue the partnership legacy of this office and lay the foundation for future impact of WU technologies, it’s my pleasure to present the OTM Annual Report for fiscal year 2016 (FY16). This year’s highlights include:

- The most new startups for a fiscal year in OTM history, as six new startup companies based on WU technology were launched in FY16. More detailed descriptions of these companies can be found on page 5.

- Recognition of WU inventors in the St. Louis community, including Dr. Sasa Mutic being honored by the St. Louis Business Journal for his contributions to medical innovation. Read more about these honors on page 9.

- A total of 103 total revenue-generating agreements and 177 invention disclosures, our highest-ever figures in both categories. Check out our full statistics on page 10.

As we look back on FY16, I want to thank the team at OTM for its tireless work in providing excellent customer service to our University inventors and continuing to build relationships in the St. Louis region and beyond. I also want to thank the leadership at WU for its support of the positive changes OTM has made and will continue to make.

In FY17, our office will add three new full-time positions as we strive to better serve our clients, strengthen existing roles, and make OTM the best resource it can be. In addition, we hope to increase our efforts to partner WU technologies, continue to help form viable startup companies, and provide more transparency into OTM practices.

If you have any questions or suggestions, feel free to let us know. Thank you for your support!

Sincerely,Nichole Mercier, PhDOTM Managing Director

3

INTRODUCTION

Nichole Mercier

4

QUICK START LICENSEThe Quick Start License, launched in January 2015, is a simplified process that allows Washington University faculty and staff to focus on the development and commercialization of products. This license streamlines the contract negotiation process and moves more products based on University IP into the marketplace.

In an effort to encourage the entrepreneurial efforts at Washington University, there are no upfront fees or performance payments in a Quick Start License. The Quick Start is also designed to make University startups more attractive to potential investors.

Quick Start Eligibility: - Founded by a University faculty member or employee who is an inventor on the licensed technology- Competent business team in place- Provide business plan or pitch deck as a basis for defining milestones

Quick Start Terms:- An exclusive license with right to sublicense- No payment for past patent costs – future patent costs to be paid by licensee- No upfront, annual, or milestone fees, and no minimum annual royalties- Fixed 2% patent royalty rate on product sales- 0.95% success fee upon company exit

FY16 Quick Start Companies

Courier Therapeutics, Inc.Founders: Drs. Alexander Krupnick & Daved Fremont

Website: www.couriertherapeutics.comDeveloping a platform technology for modulating the innate immune systems.

Accuronix TherapeuticsFounders: Drs. William Hawkins & Robert Mach

Website: www.accuronix.comDeveloping new drugs that target the sigma-2 receptor on cancer cells to deliver cytotoxic payloads.

5

STARTUPS

Cellatrix, LLCFounder: Dr. Kareem AzabWebsite: www.cellatrix.com

Provides clinical evidence for correlation with ex-vivo results in 3D Tissue-Engineered Bone Marrow.

Applied Particle Technology, LLC Founders: Jiaxi Fang & Tandeep S. ChadhaWebsite: www.appliedparticletechnology.comA provider of innovative, cost-effective air treatment & filtration solutions for specialty applications.

clEAR, LLCFounder: Dr. Nancy Tye-MurrayWebsite: www.clEARworks4ears.com“customized learning: Exercises for Aural Rehabilitation” uses games to assist hearing-loss patients.

Fimbrion TherapeuticsFounders: Scott Hultgren & Jim JanetkaWebsite: www.fimbrion.comAims to treat Urinary Tract Infections (UTI) by selectively targeting pathogenic bacteria.

The Office of Technology Management is committed to creating an environment that allows startup companies to launch and develop. With the help of University resources like Skandalaris Center and the Center for Drug Discovery, local accelerators such as BioGenerator, and others, faculty members at Washington University are encouraged to pursue commercialization through the formation of new companies. The six companies listed below were all formed during FY16.

6

COMPANY PROFILEC2N Diagnostics, LLCFounders: Drs. David Holtzman & Randall BatemanYear Formed: 2007Website: www.c2ndiagnostics.com

C2N Diagnostics, LLC is a Washington University startup and privately-held protein diagnostic and therapeutic discovery company targeting progressive neurodegeneration.

C2N formed in late 2007 by Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, and LifeTech Research, a Maryland-based technology research and commercialization firm. The company is currently located at the Center for Emerging Technologies (CET) in St. Louis.

The company’s therapeutic discovery efforts are focused around mechanism-based approaches to prevent or stop the progression of human neurological disorders.

In regards to diagnostics, C2N is leading ways to understand molecular mechanisms of brain diseases, track early progression, and measure the biologic activity of emerging therapies. By measuring the concentration and metabolism of CNS-derived biomolecules using sensitive stable isotope labeling, C2N provides novel insights into the normal and abnormal workings of the brain.

Pictured: Dr. David Holtzman (Left) and Dr. Randy Bateman (Far Right)

7

Dr. Matthew MacEwanCompany: Acera Surgical, Inc.Year Formed: 2012Website: www.acera-surgical.com

Dr. Matthew MacEwan is the President and Chief Scientist at Acera Surgical, Inc. MacEwan is the co-inventor of Acera’s nanotechnology platform and is the co-founder of the company. He is currently responsible for managing Acera’s IP and patent portfolio, new product research and the design and implementation of clinical studies.

Located in St. Louis, Acera Surgical is a medical device company producing a first-in-class line of implantable electrospun surgical materials and related tools/accessories. Previously known as Retectix, LLC, Acera was one of 36 companies chosen to present at University Startups Demo Day in Washington, D.C., hosted by the National Council of Entreprenuerial Tech Transfer in September 2016.

The company’s headline product is Cerafix®, a unique non-biologic surgical material optimally engineered for use in neurosurgical repair of dural defects. Cerafix® (seen below) is the first nanofabricated, synthetic surgical mesh to enter the surgical market. Due to its unique nanofabricated structure, Cerafix® possesses unique material and biological properties. Specifically, Cerafix® provides superior handling properties, increased ease of use, improved biocompatibility, and reduced rates of complications compared to existing products.

INVENTOR PROFILE

8

FEATURED TECHNOLOGIES

New Therapeutic for Prevention & Treatment of Osteoarthritis

Lead Innovator: Regis O’KeefeDepartment: Orthopaedic Surgery

Description: Each year, there are more than 3 million US cases of osetoarthritis, a type of arthritis that occurs via inflammation of one or more joints when flexible tissue at the ends of bones

wears down. A research team at Washington University is working towards a new therapuetic following the discovery that the expression of DNA methyltransferase enzymes (DNMT3b) is

decreased in cartilage cells. This research is aimed at developing diagnostic and therapeutic strategies to treat and potentially prevent osteoarthritis.

Monoclonal Antibodies against Zika Virus

Lead Innovator: Michael DiamondDepartment: Infectious DiseasesDescription: Scientists at Washington University School of Medicine have identified antibodies capable of protecting against the Zika virus, a significant step toward developing a vaccine, better diagnostic tests, and new forms of treatment. An outbreak of the mosquito-borne virus in the Americas has been linked to a startling surge of babies born with abnormally small heads and underdeveloped brains, a condition known as microcephaly. The research has been led by Daved Fremont, PhD and Michael Diamond, MD, PhD.

GDF15 as Biomarker for Glaucoma Severity/Progression

Lead Innovator: Rajendra ApteDepartment: OphthalmologyDescription: Glaucoma is a leading cause of blindness impacting millions of Americans. Treatments are available and effective for arresting disease progression, but cannot address any loss of vision that has already occurred. Dr. Rajendra Apte has discovered a new biomarker, GDF15, whose expression is correlated with disease progression. A test using this biomarker will be able to detect the disease at an early stage.

Rajendra Apte

Regis O’Keefe

Michael Diamond

Plasmonic Biosensors with Built-In Artificial Antibodies

Lead Innovator: Srikanth SingamaneniDepartment: Mechanical Engineering

Description: Using artificial bio receptors and metal nanostructures, this technology has set the groundwork to create durable, point-of-care (POC) diagnostics for heart attack and kidney injury.

The plasmonic sensors based on an “artificial antibody platform” could be easily implemented using a miniaturized, battery-operated spectrometer to potentially enable testing in POC settings,

such as ambulances and urgent care facilities. Srikanth Singamaneni

9

Sasa Mutic, PhDSt. Louis Business Journal Innovation AwardDr. Sasa Mutic is the head of medical physics in the Department of Radiation Oncology at Washington University in St. Louis. In addition, he is a co-founder, Senior Vice President, and Chief Technical Officer of a local startup company, Radialogica. During his time at the University, Mutic has been named an inventor on nearly 40 patents and patent applications, several of which have been licensed and used to improve devices in the clinic today. In addition to Mutic’s individual achievements, the Radiation Oncology department has transformed into a center for innovation under his leadership. The St. Louis Business Journal Innovation Awards honor a company and an individual in eight categories that span the startup and innovation industry. From cutting edge startups to established public companies, these honorees are making breakthroughs in their respective industries.

Irving Boime, PhDWashington University Chancellor’s Award

Dr. Irving Boime is a professor of developmental biology and of obstetrics and gynecology at the Washington University School of Medicine. Boime’s research has focused on numerous

investigations of the structure and function of pituitary and placenta hormones. His work has resulted in new therapeutics to treat human infertility and growth disorders, as well

as support animal husbandry in agriculture. The technology he and his team developed increases the amount of time key hormones remain stable in the bloodstream. Working

with Washington University’s Office of Technology Management, these patents have been licensed by numerous pharmaceutical companies. The Chancellor’s Award for Innovation

and Entrepreneurship goes to a WUSTL faculty member selected by the chancellor for special and significant contributions in innovation and entrepreneurship.

OUTREACH

Women in Innovation & Technology SeriesThe Women in Innovation and Technology (WIT) program provides female faculty and post-doctoral researchers an understanding of inventing and commercializing academic findings. Entering its fourth year, the program also introduces participants to a number of entrepreurial support organizations in the St. Louis area, along with various networking events that provide attendees with opportunities to grow their commercialization networks.

In FY17, the WIT program will consist of a celebratory luncheon in November 2016, a one-day symposium in February 2017, and periodic networking events in the months to follow. For more information and updates on the program, visit the WIT page on our OTM website.

Sasa Mutic

Irving Boime

AWARD RECIPIENTS

EVENTS

10

FY16 STATISTICS

0

20

40

60

80

100

120

140

160

180

FY12 FY13 FY14 FY15 FY16

164155

143157

177

Invention Disclosures

0

50

100

150

200

250

300

FY12 FY13 FY14 FY15 FY16

179203

215

275 271

Patents

0

20

40

60

80

100

120

FY12 FY13 FY14 FY15 FY16

5246 48

74

103

Agreements

0

5

10

15

20

25

30

35

FY12 FY13 FY14 FY15 FY16

6.2 6.99

30.6

10

Revenue*In Millions of Dollars

177INVENTION DISCLOSURES

WU RECORD

103EXECUTED AGREEMENTS

WU RECORD

$10MIN REVENUE

271FILED PATENTS

11

Managing DirectorNichole Mercier, PhD

Licensing TeamLeena Prabhu, PhD - Associate Director

Paul Carter - Business Development DirectorPaul Hippenmeyer, PhD - Business Development Director

David Silva, PhD - Business Development DirectorMichael Muskus, PhD - Business Development Associate

Scott Crick, PhD - Licensing AssociateJennifer Richards, PhD - Licensing Associate

Contract & Patent TeamCarl Morrell - Contracts Manager

Alison Carter - Contracts CoordinatorGina Smutz - Contracts Coordinator

Carol Priddy - IP AdministratorJulie Longmeyer - Docket Clerk

Finance & Administrative TeamRob Reardon - Sr. Business Manager

Sarah Kaye - Assistant Accountant IIEvelyn Pena - Assistant Accountant II

Tom Rodgers - Communications & Outreach ManagerAmy Johnson - Administrative Coordinator

Vice ChancellorDedric Carter, PhD

Vice Chancellor for Operations and Technology Transfer

Physical Address:4240 Duncan Ave. (Suite 110)

St. Louis, MO 63110

Mailing Address:660 S. Euclid, CB 8013

St. Louis, MO 63110

P: 314-747-0920F: 314-362-5872

E: otm@dom.wustl.edu

www.otm.wustl.edu